Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients With Previous Statin Intolerance

American Journal of Cardiology

Volumn 105, Issue 2, 2010, Pages 198-204

  Halbert, Steven C ^a,b   French, Benjamin ^a   Gordon, Ram Y ^c   Farrar, John T ^a   Schmitz, Kathryn ^a   Morris, Patti B ^c   Thompson, Paul D ^d   Rader, Daniel J ^a   Becker, David J ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Jefferson Myrna Brind Center for Integrative Medicine   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CHOLESTIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOATING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FATIGUE; FEMALE; FRACTURE; HEADACHE; HEALTH PROGRAM; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MALE; MOTOR COORDINATION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATIN ASSOCIATED MYALGIA; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

AGED; BIOLOGICAL PRODUCTS; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCULAR DISEASES; PRAVASTATIN; RECURRENCE; TREATMENT OUTCOME;

EID: 73149101073     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.08.672     Document Type: Article

References (28)

1. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
2. Li Y.G., Zhang F., Wang Z.T., and Hu Z.B. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal 35 (2004) 1101-1112
3. Ma J., Li Y., Ye Q., Li J., Hua Y., Ju D., Zhang D., Cooper R., and Chang M. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48 (2000) 5220-5225
4. Supplement Business Report 2009 (2009), Nutrition Business Journal, Boulder, CO 44
5. Becker D.J., Gordon R.Y., Morris P.B., Yorko J., Gordon Y.J., Li M., and Iqbal N. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 83 (2008) 758-764
6. Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R.M., and Go V.L. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69 (1999) 231-236
7. Lu Z., Kou W., Du B., Wu Y., Zhao S., Brusco O.A., Morgan J.M., Capuzzi D.M., and Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101 (2008) 1689-1693
8. Becker D.J., Gordon J., Halbert S.C., French B., Morris P.B., and Rader D.J. Red yeast rice versus placebo in dyslipidemic, statin-intolerant patients enrolled in a therapeutic lifestyle program: a randomized, controlled trial. Ann Intern Med 150 (2009) 830-839
9. Keller S., Bann C.M., Dodd S.L., Schein J., Mendoza T.R., and Cleeland C.S. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20 (2004) 309-318
10. Martin H.J., Yule V., Syddall H.E., Dennison E.M., Cooper C., and Aihie S.A. Is hand-held dynamometry useful for the measurement of quadriceps strength in older people?. A comparison with the gold standard Bodex dynamometry. Gerontology 52 (2006) 154-159
11. Thomson C.A., Giuliano A., Rock C.L., Ritenbaugh C.K., Flatt S.W., Faerber S., Newman V., Caan B., Graver E., Hartz V., Whitacre R., Parker F., Piece J.P., and Marshall J.R. Measuring dietary change in a diet intervention trial: comparing food frequency questionnaire and dietary recalls. Am J Epidemiol 157 (2003) 754-762
12. Paffenbarger Jr. R.S., Hyde R.T., Wing A.L., and Hsieh C.C. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 314 (1986) 605-613
13. Dallal G. Randomization.com. www.randomization.com Accessed May 2, 2008
14. Bruckert E., Hayem G., Dejager S., Yau C., and Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19 (2005) 403-414
15. Liang K.-Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
16. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 14 (1982) 473-482
17. Hansen K.E., Hildebrand J.P., Ferguson E.E., and Stein J.H. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165 (2005) 2671-2676
18. Backes J.M., Moriarty P.M., Ruisinger J.F., and Gibson C.A. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 100 (2007) 554-555
19. Gadarla M., Kearns A.K., and Thompson P.D. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 101 (2008) 1747-1748
20. Backes J.M., Venero C.V., Gibson C.A., Ruisinger J.F., Howard P.A., Thompson P.D., and Moriarty P.M. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 42 (2008) 341-346
21. Glueck C.J., Aregawi D., Agloria M., Khalil Q., Winiarska M., Munjal J., Gogineni S., and Wang P. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther 28 (2006) 933-942
22. Stein E.A., Ballantyne C.M., Windler E., Simes P.A., Sussekov A., Yigit Z., Seper C., and Gimpelewicz C.R. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 101 (2008) 490-496
23. Mackie B.D., Satija S., Nell C., Miller J., and Sperling L.S. Monday, Wednesday and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol 99 (2007) 291
24. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 97 (2006) 44C-51C
25. Li Z., Seeram N.P., Lee R., Thames G., Minutti C., Wang H.J., and Heber D. Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers. J Altern Complement Med 11 (2005) 1031-1038
26. Thompson P.D., Clarkson P.M., and Rosenson R.S. An assessment of statin safety by muscle experts. Am J Cardiol 97 (2006) 69C-76C
27. Franc S., Dejager S., Bruckert E., Chauvenet M., Giral P., and Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 17 (2003) 459-465
28. Heber D., Lembertas A., Lu Q.Y., Bowerman S., and Go V.L. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 7 (2001) 133-139